metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis La elevación del colesterol unido a lipoproteínas de alta densidad: perspectiv...
Información de la revista
Vol. 22. Núm. S1.
Jornada sobre HDL
Páginas 44-48 (abril 2010)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 22. Núm. S1.
Jornada sobre HDL
Páginas 44-48 (abril 2010)
Jornada sobre HDL
Acceso a texto completo
La elevación del colesterol unido a lipoproteínas de alta densidad: perspectiva futura. La CETP como diana terapéutica
Elevation of high-density lipoprotein cholesterol: future perspective. Cholesteryl ester transfer protein as a therapeutic target
Visitas
2995
F. Civeira
Autor para correspondencia
civeira@unizar.es

Autor para correspondencia.
, R. Mateo-Gallego, E. Burillo, A. Cenarro
Unidad de Lípidos y Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud (I+CS), Universidad de Zaragoza, Zaragoza, España
Este artículo ha recibido
Información del artículo
Resumen

La CETP (cholesteryl ester transfer protein) es la proteína responsable de la transferencia de lípidos neutros entre las lipoproteínas. La CETP juega un papel clave en la homeostasis del colesterol, especialmente en la redistribución de colesterol entre partículas y en el transporte reverso de colesterol, por lo que la modificación de su actividad puede modificar el desarrollo y la evolución de la ateromatosis. Los efectos de la inhibición de CETP incluyen: reducción de colesterol LDL y aumento del colesterol HDL y apo A-1, aumento en el tamaño de las partículas LDL y HDL, y reducción del colesterol en las partículas ricas en triglicéridos. En consonancia, la inducción de expresión de la actividad CETP en ratones aumenta la susceptibilidad a la aterosclerosis mientras que la inhibición de la actividad CETP en conejos tiende a reducir su desarrollo. Sin embargo, el papel de la inhibición de CETP en la ateromatosis en humanos está todavía por definir.

Palabras clave:
CETP
Ateromatosis
HDL
Inhibición de CETP
Abstract

Cholesteryl ester transfer protein (CETP) facilitates transfer of neutral lipids between lipoprotein classes. CETP plays a key role in cholesterol homeostasis, especially in the redistribution of cholesterol among particles and in reverse cholesterol transport. Consequently, modifying the activity of this protein could influence the development and progression of atheromatosis. The effects of inhibiting CETP include reductions in lowdensity lipoprotein (LDL)-cholesterol and cholesterol in triglyceride-rich particles and increases in high-density lipoprotein (HDL)-cholesterol, apolipoprotein A-1 and the size of LDL and HDL particles. The induction of expression of CETP activity in mice increases susceptibility to atherosclerosis, while inhibition of CETP activity in rabbits tends to reduce its development. However, the role of CETP inhibition in atheromatosis in humans remains to be established.

Keywords:
CETP
Atheromatosis
HDL
CETP inhibition
El Texto completo está disponible en PDF
Bibliografía
[1.]
P.K. Shah.
The Yin and Yang of cholesteryl ester transfer protein in cardiovascular disease.
Circulation, 120 (2009), pp. 2408-2410
[2.]
O. Stein, Y. Stein.
Lipid transfer proteins (LTP) and atherosclerosis.
Atherosclerosis, 178 (2005), pp. 217-230
[3.]
M. Vergeer, E.S. Stroes.
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Am J Cardiol, 104 (2009), pp. 32E-38E
[4.]
M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, R.W. Clark, et al.
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
N Engl J Med, 350 (2004), pp. 1505-1515
[5.]
A.R. Tall.
The effects of cholesterol ester transfer protein inhibition on cholesterol efflux.
Am J Cardiol, 104 (2009), pp. 39E-45E
[6.]
F. Matsuura, N. Wang, W. Chen, X.C. Jiang, A.R. Tall.
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway.
J Clin Invest, 116 (2006), pp. 1435-1442
[7.]
L. Yvan-Charvet, F. Matsuura, N. Wang, M.J. Bamberger, T. Nguyen, F. Rinninger, et al.
Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
Arterioscler Thromb Vasc Biol, 27 (2007), pp. 1132-1138
[8.]
P.J. Barter, H.B. Brewer Jr, M.J. Chapman, C.H. Hennekens, D.J. Rader, A.R. Tall.
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
Arterioscler Thromb Vasc Biol, 23 (2003), pp. 160-167
[9.]
A.S. Plump, L. Masucci-Magoulas, C. Bruce, C.L. Bisgaier, J.L. Breslow, A.R. Tall.
Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.
Arterioscler Thromb Vasc Biol, 19 (1999), pp. 1105-1110
[10.]
B. Foger, M. Chase, M.J. Amar, B.L. Vaisman, R.D. Shamburek, B. Paigen, et al.
Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.
J Biol Chem, 274 (1999), pp. 36912-36920
[11.]
H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, H. Shinkai.
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
Nature, 406 (2000), pp. 203-207
[12.]
A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R.P. Dullaart, et al.
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.
JAMA, 299 (2008), pp. 2777-2788
[13.]
P.M. Ridker, G. Paré, A.N. Parker, R.Y. Zee, J.P. Miletich, D.I. Chasman.
Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genome wide analysis among 18 245 initially healthy women from the Women's Genome Health Study.
Circ Cardiovasc Genet, 2 (2009), pp. 26-33
[14.]
J.D. Curb, R.D. Abbott, B.L. Rodríguez, K. Masaki, R. Chen, D.S. Sharp, et al.
A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly.
J Lipid Res, 45 (2004), pp. 948-953
[15.]
B. Agerholm-Larsen, B.G. Nordestgaard, R. Steffensen, G. Jensen, A. Tybjaerg-Hansen.
Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene.
Circulation, 101 (2000), pp. 1907-1912
[16.]
R.P. Dullaart, W.J. Sluiter.
Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis.
Pharmacogenomics, 9 (2008), pp. 747-763
[17.]
P. Marschang, A. Sandhofer, A. Ritsch, I. Fiser, E. Kvas, J.R. Patsch.
Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
J Intern Med, 260 (2006), pp. 151-159
[18.]
S.M. Boekholdt, J.A. Kuivenhoven, N.J. Wareham, R.J. Peters, J.W. Jukema, R. Luben, et al.
Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)- Norfolk population study.
Circulation, 110 (2004), pp. 1418-1423
[19.]
R.S. Vasan, M.J. Pencina, S.J. Robins, J.P. Zachariah, G. Kaur, R.B. D’Agostino, et al.
Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.
Circulation, 120 (2009), pp. 2414-2420
[20.]
P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, ILLUMINATE Investigators, et al.
Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med, 357 (2007), pp. 2109-2122
Copyright © 2010. Sociedad Española de Arteriosclerosis y Elsevier España S.L.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos